Skip to content
For US Healthcare Professionals
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Logo
For US Healthcare Professionals
About HER2+ (IHC 3+) Metastatic Solid Tumors

Regardless of biomarker status

Despite treatment advances, long-term outcomes remain poor across many metastatic solid tumors1-8

  • 5-year relative survival ranges from 3% to 32% across metastatic solid tumors1-8,a
  • Biomarkers may act as oncogenic drivers and contribute to a more aggressive form of disease9

aBased on US SEER data from 2015-2021.

In patients with metastatic solid tumors

HER2+ (IHC 3+) is an oncogenic driver that can result in a more aggressive cancer10-18

Prevalence of HER2+ (IHC 3+) in select solid tumorsb

Tumor type HER2+ (IHC 3+) prevalence
Biliary tract17,19,20 4%-13%
Bladder19,21-24 4%-31%
Cervical19,25,26 8%-14%
CRC19,27,28 1%-3%
Endometrial15,19,29-31 4%-28%
NSCLC19,32-34 1%-5%
Ovarian19,35-38 1%-5%
Pancreatic19,39,40 1%-7%

bIndividual tumor prevalence numbers reflect US and ex-US populations. Due to limited testing of IHC in the US, data from a global population have been included.

The prevalence of HER2+ (IHC 3+) is often greater than or similar to the rates of other HER2 alterations15,17,19-56

HER2+ (IHC 3+) can occur in the absence of HER2 (ERBB2) amplification or mutation57

HER2 overexpression (IHC 3+) is a distinct biomarker from HER2 (ERBB2) amplification and mutation58-61

Alteration HER2 protein overexpression HER2 (ERBB2) amplification HER2 (ERBB2) mutation
Biology Overabundance of HER2 receptors on the surface of a cell Abnormally high number of HER2 (ERBB2) gene copies Mutation in the HER2 (ERBB2) gene
Test IHC FISH or NGS NGS
Alteration
HER2 protein overexpression HER2 (ERBB2) amplification HER2 (ERBB2) mutation
Biology
Overabundance of HER2 receptors on the surface of a cell Abnormally high number of HER2 (ERBB2) gene copies Mutation in the HER2 (ERBB2) gene
Test
IHC FISH or NGS NGS

Identifying patients with a HER2+ (IHC 3+) metastatic solid tumor can inform treatment decisions62

HER2+ (IHC 3+) is actionable in metastatic solid tumors62

Proactively identify previously treated patients with HER2+ (IHC 3+) metastatic solid tumors who may be eligible for treatment with ENHERTU60,62,63

Plan ahead to ensure adult patients with metastatic solid tumors are tested for HER2+ (IHC 3+)58,60,62

  • For newly diagnosed patients, order HER2 IHC testing to inform future treatment plans upon progression
  • For currently treated patients, look back at previous results to determine if your patient has a HER2+ (IHC 3+) metastatic solid tumor

Ensure every patient with a metastatic solid tumor receives HER2 IHC testing as part of your comprehensive biomarker workup, even if NGS was already performed62

LISTED IN NCCN GUIDELINES®

FAM-TRASTUZUMAB DERUXTECAN-NXKI (ENHERTU) IS RECOMMENDED IN NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY (NCCN GUIDELINES®) ACROSS MULTIPLE METASTATIC SOLID TUMORS

Fam-trastuzumab deruxtecan-nxki (ENHERTU) is recommended across multiple metastatic solid tumors
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommends fam-trastuzumab deruxtecan-nxki (ENHERTU) as a HER2-directed treatment option for previously treated patients with the following solid tumors64-78,c: NCCN Guidelines® recommends fam-trastuzumab deruxtecan-nxki (ENHERTU) as a HER2-directed treatment option for previously treated patients with the following solid tumors64-78,c:

Visit NCCN.org for more information

ENHERTU is approved in HER2+ (IHC 3+) metastatic solid tumors and was studied across 16 tumor types. The tumor types listed above are based on guideline recommendations and may differ from the tumor types studied in the clinical trials.62

cPlease see NCCN Guidelines for patient selection criteria.

Learn about HER2 IHC testing across metastatic solid tumors

Download the HER2 Testing Guide for Pathologists  

ASCO-CAP, American Society of Clinical Oncology-College of American Pathologists; CRC, colorectal cancer; ERBB2, erb-b2 receptor tyrosine kinase 2; FISH, fluorescence in situ hybridization; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; NCCN, National Comprehensive Cancer Network® (NCCN®); NGS, next-generation sequencing; NSCLC, non-small cell lung cancer; SEER, Surveillance, Epidemiology, and End Results Program.

INDICATION AND IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNINGS Expand

WARNING: INTERSTITIAL LUNG DISEASE and EMBRYO-FETAL TOXICITY

  • Interstitial lung disease (ILD) and pneumonitis, including fatal cases, have been reported with ENHERTU. Monitor for and promptly investigate signs and symptoms including cough, dyspnea, fever, and other new or worsening respiratory symptoms. Permanently discontinue ENHERTU in all patients with Grade 2 or higher ILD/pneumonitis. Advise patients of the risk and to immediately report symptoms.
  • Exposure to ENHERTU during pregnancy can cause embryo-fetal harm. Advise patients of these risks and the need for effective contraception.
INDICATION

ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated:

  • HER2-Positive (IHC 3+) Unresectable or Metastatic Solid Tumors

    • As monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options

      This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Contraindications

None.

Warnings and Precautions

Interstitial Lung Disease / Pneumonitis

Severe, life-threatening, or fatal interstitial lung disease (ILD), including pneumonitis, can occur in patients treated with ENHERTU. A higher incidence of Grade 1 and 2 ILD/pneumonitis has been observed in patients with moderate renal impairment. Advise patients to immediately report cough, dyspnea, fever, and/or any new or worsening respiratory symptoms. Monitor patients for signs and symptoms of ILD. Promptly investigate evidence of ILD. Evaluate patients with suspected ILD by radiographic imaging. Consider consultation with a pulmonologist. For asymptomatic ILD/pneumonitis (Grade 1), interrupt ENHERTU until resolved to Grade 0, then if resolved in ≤28 days from date of onset, maintain dose. If resolved in >28 days from date of onset, reduce dose 1 level. Consider corticosteroid treatment as soon as ILD/pneumonitis is suspected (e.g., ≥0.5 mg/kg/day prednisolone or equivalent). For symptomatic ILD/pneumonitis (Grade 2 or greater), permanently discontinue ENHERTU. Promptly initiate systemic corticosteroid treatment as soon as ILD/pneumonitis is suspected (e.g., ≥1 mg/kg/day prednisolone or equivalent) and continue for at least 14 days followed by gradual taper for at least 4 weeks.

Solid Tumors (IHC 3+) and Other Solid Tumors (5.4 mg/kg)

In patients treated with ENHERTU 5.4 mg/kg, ILD occurred in 12% of patients. Median time to first onset was 5.5 months (range: 0.9 to 31.5). Fatal outcomes due to ILD and/or pneumonitis occurred in 0.9% of patients treated with ENHERTU.

Neutropenia

Severe neutropenia, including febrile neutropenia, can occur in patients treated with ENHERTU. Monitor complete blood counts prior to initiation of ENHERTU and prior to each dose, and as clinically indicated. For Grade 3 neutropenia (Absolute Neutrophil Count [ANC] <1.0 to 0.5 x 109/L), interrupt ENHERTU until resolved to Grade 2 or less, then maintain dose. For Grade 4 neutropenia (ANC <0.5 x 109/L), interrupt ENHERTU until resolved to Grade 2 or less, then reduce dose by 1 level. For febrile neutropenia (ANC <1.0 x 109/L and temperature >38.3º C or a sustained temperature of ≥38º C for more than 1 hour), interrupt ENHERTU until resolved, then reduce dose by 1 level.

Solid Tumors (IHC 3+) and Other Solid Tumors (5.4 mg/kg)

In patients treated with ENHERTU 5.4 mg/kg, a decrease in neutrophil count was reported in 65% of patients. Nineteen percent had Grade 3 or 4 decreased neutrophil count. Median time to first onset of decreased neutrophil count was 22 days (range: 2 to 939). Febrile neutropenia was reported in 1.2% of patients.

Left Ventricular Dysfunction

Patients treated with ENHERTU may be at increased risk of developing left ventricular dysfunction. Left ventricular ejection fraction (LVEF) decrease has been observed with anti-HER2 therapies, including ENHERTU. Assess LVEF prior to initiation of ENHERTU and at regular intervals during treatment as clinically indicated. Manage LVEF decrease through treatment interruption. When LVEF is >45% and absolute decrease from baseline is 10-20%, continue treatment with ENHERTU. When LVEF is 40-45% and absolute decrease from baseline is <10%, continue treatment with ENHERTU and repeat LVEF assessment within 3 weeks. When LVEF is 40-45% and absolute decrease from baseline is 10-20%, interrupt ENHERTU and repeat LVEF assessment within 3 weeks. If LVEF has not recovered to within 10% from baseline, permanently discontinue ENHERTU. If LVEF recovers to within 10% from baseline, resume treatment with ENHERTU at the same dose. When LVEF is <40% or absolute decrease from baseline is >20%, interrupt ENHERTU and repeat LVEF assessment within 3 weeks. If LVEF of <40% or absolute decrease from baseline of >20% is confirmed, permanently discontinue ENHERTU. Permanently discontinue ENHERTU in patients with symptomatic congestive heart failure. Treatment with ENHERTU has not been studied in patients with a history of clinically significant cardiac disease or LVEF <50% prior to initiation of treatment.

Solid Tumors (IHC 3+) and Other Solid Tumors (5.4 mg/kg)

In patients treated with ENHERTU 5.4 mg/kg, LVEF decrease was reported in 4.6% of patients, of which 0.6% were Grade 3 or 4.

Embryo-Fetal Toxicity

ENHERTU can cause fetal harm when administered to a pregnant woman. Advise patients of the potential risks to a fetus. Verify the pregnancy status of females of reproductive potential prior to the initiation of ENHERTU. Advise females of reproductive potential to use effective contraception during treatment and for 7 months after the last dose of ENHERTU. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with ENHERTU and for 4 months after the last dose of ENHERTU.

Additional Dose Modifications

Thrombocytopenia

For Grade 3 thrombocytopenia (platelets <50 to 25 x 109/L) interrupt ENHERTU until resolved to Grade 1 or less, then maintain dose. For Grade 4 thrombocytopenia (platelets <25 x 109/L) interrupt ENHERTU until resolved to Grade 1 or less, then reduce dose by 1 level.

Adverse Reactions

Solid Tumors (IHC 3+) and Other Solid Tumors (5.4 mg/kg)

The pooled safety population reflects exposure to ENHERTU 5.4 mg/kg intravenously every 3 weeks in 2233 patients in Study DS8201-A-J101 (NCT02564900), DESTINY-Breast01, DESTINY-Breast02, DESTINY-Breast03, DESTINY-Breast04, DESTINY-Breast06, DESTINY-Lung01, DESTINY-Lung02, DESTINY-CRC02, and DESTINY-PanTumor02. Among these patients, 67% were exposed for >6 months and 38% were exposed for >1 year. In this pooled safety population, the most common (≥20%) adverse reactions, including laboratory abnormalities, were decreased white blood cell count (73%), nausea (72%), decreased hemoglobin (67%), decreased neutrophil count (65%), decreased lymphocyte count (60%), fatigue (55%), decreased platelet count (48%), increased aspartate aminotransferase (46%), increased alanine aminotransferase (44%), increased blood alkaline phosphatase (39%), vomiting (38%), alopecia (37%), constipation (32%), decreased blood potassium (32%), decreased appetite (31%), diarrhea (30%), and musculoskeletal pain (24%).

HER2-Positive (IHC 3+) Unresectable or Metastatic Solid Tumors

The safety of ENHERTU was evaluated in 347 adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who received ENHERTU 5.4 mg/kg intravenously once every 3 weeks in DESTINY-Breast01, DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02. The median duration of treatment was 8.3 months (range 0.7 to 30.2).

Serious adverse reactions occurred in 34% of patients receiving ENHERTU. Serious adverse reactions in >1% of patients who received ENHERTU were sepsis, pneumonia, vomiting, urinary tract infection, abdominal pain, nausea, pneumonitis, pleural effusion, hemorrhage, COVID-19, fatigue, acute kidney injury, anemia, cellulitis, and dyspnea. Fatalities due to adverse reactions occurred in 6.3% of patients including ILD/pneumonitis (2.3%), cardiac arrest (0.6%), COVID-19 (0.6%), and sepsis (0.6%). The following events occurred in 1 patient each (0.3%): acute kidney injury, cerebrovascular accident, general physical health deterioration, pneumonia, and hemorrhagic shock.

ENHERTU was permanently discontinued in 15% of patients, of which ILD/pneumonitis accounted for 10%. Dose interruptions due to adverse reactions occurred in 48% of patients. The most frequent adverse reactions (>2%) associated with dose interruption were decreased neutrophil count, anemia, COVID-19, fatigue, decreased white blood cell count, and ILD/pneumonitis. Dose reductions occurred in 27% of patients treated with ENHERTU. The most frequent adverse reactions (>2%) associated with dose reduction were fatigue, nausea, decreased neutrophil count, ILD/pneumonitis, and diarrhea.

The most common (≥20%) adverse reactions, including laboratory abnormalities, were decreased white blood cell count (75%), nausea (69%), decreased hemoglobin (67%), decreased neutrophil count (66%), fatigue (59%), decreased lymphocyte count (58%), decreased platelet count (51%), increased aspartate aminotransferase (45%), increased alanine aminotransferase (44%), increased blood alkaline phosphatase (36%), vomiting (35%), decreased appetite (34%), alopecia (34%), diarrhea (31%), decreased blood potassium (29%), constipation (28%), decreased sodium (22%), stomatitis (20%), and upper respiratory tract infection (20%).

Use in Specific Populations

  • Pregnancy: ENHERTU can cause fetal harm when administered to a pregnant woman. Advise patients of the potential risks to a fetus. There are clinical considerations if ENHERTU is used in pregnant women, or if a patient becomes pregnant within 7 months after the last dose of ENHERTU.
  • Lactation: There are no data regarding the presence of ENHERTU in human milk, the effects on the breastfed child, or the effects on milk production. Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment with ENHERTU and for 7 months after the last dose.
  • Females and Males of Reproductive Potential: Pregnancy testing: Verify pregnancy status of females of reproductive potential prior to initiation of ENHERTU. Contraception: Females: ENHERTU can cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential to use effective contraception during treatment with ENHERTU and for 7 months after the last dose. Males: Advise male patients with female partners of reproductive potential to use effective contraception during treatment with ENHERTU and for 4 months after the last dose. Infertility: ENHERTU may impair male reproductive function and fertility.
  • Pediatric Use: Safety and effectiveness of ENHERTU have not been established in pediatric patients.
  • Geriatric Use: Of the 192 patients with HER2-positive (IHC 3+) unresectable or metastatic solid tumors treated with ENHERTU 5.4 mg/kg in DESTINY-PanTumor02, DESTINY-Lung01, or DESTINY-CRC02, 39% were ≥65 years and 9% were ≥75 years. No overall differences in efficacy or safety were observed between patients ≥65 years of age compared to younger patients.
  • Renal Impairment: A higher incidence of Grade 1 and 2 ILD/pneumonitis has been observed in patients with moderate renal impairment. Monitor patients with moderate renal impairment more frequently. The recommended dosage of ENHERTU has not been established for patients with severe renal impairment (CLcr <30 mL/min).
  • Hepatic Impairment: In patients with moderate hepatic impairment, due to potentially increased exposure, closely monitor for increased toxicities related to the topoisomerase inhibitor, DXd. The recommended dosage of ENHERTU has not been established for patients with severe hepatic impairment (total bilirubin >3 times ULN and any AST).

To report SUSPECTED ADVERSE REACTIONS, contact Daiichi Sankyo, Inc. at 1-877-437-7763 or FDA at 1-800-FDA-1088 or fda.gov/medwatch.

To report SUSPECTED ADVERSE REACTIONS, contact Daiichi Sankyo, Inc. at 1-877-437-7763 or FDA at 1-800-FDA-1088 or fda.gov/medwatch.

Please click here for full Prescribing Information, including Boxed WARNINGS, and click here for Medication Guide.

INDICATION

ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated:

  • HER2-Positive (IHC 3+) Unresectable or Metastatic Solid Tumors

    • As monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options

      This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

References
  • Surveillance, Epidemiology, and End Results (SEER) Program. SEER Cancer Stat Facts: Liver and Intrahepatic Bile Duct Cancer. National Cancer Institute. Accessed July 14, 2025. https://seer.cancer.gov/statfacts/html/livibd.html
  • Surveillance, Epidemiology, and End Results (SEER) Program. SEER Cancer Stat Facts: Uterine Cancer. National Cancer Institute. Accessed December 12, 2025. https://seer.cancer.gov/statfacts/html/corp.html
  • Surveillance, Epidemiology, and End Results (SEER) Program. SEER Cancer Stat Facts: Lung and Bronchus Cancer. National Cancer Institute. Accessed July 14, 2025. https://seer.cancer.gov/statfacts/html/lungb.html
  • Surveillance, Epidemiology, and End Results (SEER) Program. SEER Cancer Stat Facts: Ovarian Cancer. National Cancer Institute. Accessed December 12, 2025. https://seer.cancer.gov/statfacts/html/ovary.html
  • Surveillance, Epidemiology, and End Results (SEER) Program. SEER Cancer Stat Facts: Pancreatic Cancer. National Cancer Institute. Accessed July 14, 2025. https://seer.cancer.gov/statfacts/html/pancreas.html
  • Surveillance, Epidemiology, and End Results (SEER) Program. SEER Cancer Stat Facts: Bladder Cancer. National Cancer Institute. Accessed February 19, 2025. https://seer.cancer.gov/statfacts/html/urinb.html
  • Surveillance, Epidemiology, and End Results (SEER) Program. SEER Cancer Stat Facts: Colorectal Cancer. National Cancer Institute. Accessed July 14, 2025. https://seer.cancer.gov/statfacts/html/colorect.html
  • Surveillance, Epidemiology, and End Results (SEER) Program. SEER Cancer Stat Facts: Cervical Cancer. National Cancer Institute. Accessed December 12, 2025. https://seer.cancer.gov/statfacts/html/cervix.html
  • Vidwans SJ, et al. Oncoscience. 2014;1(10):614-623.
  • Sartore-Bianchi, et al. Oncologist. 2019;24(10):1395-1402.
  • Liu L, et al. J Thorac Oncol. 2010;5(12):1922-1932.
  • Kim EK, et al. PLoS One. 2017;12(2):e0171280.
  • Gan K, et al. Front Oncol. 2021;11:653491.
  • Morrison C, et al. J Clin Oncol. 2006;24(15):2376-2385.
  • Halle MK, et al. Br J Cancer. 2018;118(3):378-387.
  • Luo H, et al. PLoS One. 2018;13(1):e0191972.
  • Vivaldi C, et al. Oncologist. 2020;25(10):886-893.
  • Komoto M, et al. Cancer Sci. 2009;100(7):1243-1247.
  • Uzunparmak B, et al. Ann Oncol. 2023;34(11):1035-1046.
  • Roa I, et al. Gastrointest Cancer Res. 2014;7(2):42-48.
  • Fleischmann A, et al. Eur Urol. 2011;60(2):350-357.
  • Gårdmark T, et al. BJU Int. 2005;95(7):982-986.
  • Moustakas G, et al. J Int Med Res. 2020;48(1):300060519895847.
  • Moktefi A, et al. Mod Pathol. 2018;31(8):1270-1281.
  • Shi H, et al. J Pathol Clin Res. 2021;7(1):86-95.
  • Panek G, et al. Gin Onkol. 2007;5(4):218-235.
  • Heppner BI, et al. Br J Cancer. 2014;111(10):1977-1984.
  • Wang X-Y, et al. World J Gastrointest Oncol. 2019;11(4):335-347.
  • Semiz HS, et al. Turk Patoloji Derg. 2023;39(1):55-63.
  • Buza N, et al. Mod Pathol. 2013;26(12):1605-1612.
  • Vermij L, et al. Histopathology. 2021;79(4):533-543.
  • Heinmöller P, et al. Clin Cancer Res. 2003;9(14):5238-5244.
  • Zinner RG, et al. Lung Cancer. 2004;44(1):99-110.
  • Takenaka M, et al. Anticancer Res. 2011;31(12):4631-4636.
  • Tuefferd M, et al. PLoS One. 2007;2(11):e1138.
  • Ersoy E, et al. Int J Gynecol Pathol. 2022;41(4):313-319.
  • Pils D, et al. Br J Cancer. 2007;96(3):485-491.
  • Chung YW, et al. J Gynecol Oncol. 2019;30(5):e75.
  • Chou A, et al. Genome Med. 2013;5(8):78.
  • Han SH, et al. Diagnostics (Basel). 2021;11(4):653.
  • Harder J, et al. World J Gastroenterol. 2009;15(36):4511-4517.
  • Nakazawa K, et al. J Pathol. 2005;206(3):356-365.
  • Dumbrava EEI, et al. JCO Precis Oncol. 2019;3:PO.18.00345.
  • Connell CM, et al. ESMO Open. 2017;2(5):e000279. Published online November 24, 2017. doi:10.1136/esmoopen-2017-000279
  • Li M, et al. Nat Genet. 2014;46(8):872-876.
  • Chmielecki J, et al. Oncologist. 2015;20(1):7-12.
  • Li X, et al. World J Surg Oncol. 2016;14(1):38.
  • Subramanian J, et al. Oncologist. 2019;24(12):e1303-e1314.
  • Nagasaka M, et al. Clin Lung Cancer. 2022;23(1):52-59.
  • Volckmar AL, et al. Int J Cancer. 2019;145(3):649-661.
  • Zhuo X, et al. J Cancer Res Clin Oncol. 2023;149(5):2029-2039.
  • Zhao J, et al. JCO Precis Oncol. 2020;4:411-425.
  • Henry JT, et al. Chin Clin Oncol. 2019;8(5):49.
  • El-Deiry WS, et al. Cancer Biol Ther. 2015;16(12):1726-1737.
  • Seo AN, et al. PLoS One. 2014;9(5):e98528.
  • Raghav KPS, et al. J Clin Oncol. 2023;41(suppl 16):3501.
  • Ismail A, et al. Oncologist. 2025;30(9):oyaf258.
  • Wolff AC, et al. Arch Pathol Lab Med. 2023;147(9):993-1000.
  • Ren S, et al. [Published correction appears in ESMO Open. 2022;7(3):100482]. ESMO Open. 2022;7(1):100395. Published online February 8, 2022. doi:10.1016/j.esmoop.2022.100395
  • Bartley AN, et al. J Clin Oncol. 2017;35(4):446-464.
  • Morsberger L, et al. Cancer Cell Int. 2022;22(1):350.
  • ENHERTU. Prescribing information. Daiichi Sankyo, Inc.; 2025.
  • Data on file. Daiichi Sankyo, Inc. Basking Ridge, NJ.
  • Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Ampullary Adenocarcinoma V.2.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed January 10, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  • Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Appendiceal Neoplasms and Cancers V.1.2026. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed October 30, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  • Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Biliary Tract Cancers V.2.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed July 2, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  • Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Bladder Cancer V.3.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed December 19, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  • Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Cervical Cancer V.2.2026. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed November 10, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  • Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Colon Cancer V.5.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed October 30, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  • Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Rectal Cancer V.4.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed October 31, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  • Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Uterine Neoplasms V.2.2026. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed November 14, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  • Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Head and Neck Cancers V.1.2026. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed December 8, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  • Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer V.2.2026. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed December 2, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  • Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Occult Primary V.1.2026. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed October 21, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  • Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer V.3.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed July 16, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  • Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Pancreatic Adenocarcinoma V.2.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed February 3, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  • Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Vaginal Cancer V.2.2026. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed December 4, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  • Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Vulvar Cancer V.1.2026. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed November 7, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
Back to top